1-Benzyl-1,4-diazepane
CAS: 4410-12-2
Ref. 3D-FB116984
| 1g | Discontinued | ||
| 2g | Discontinued | ||
| 5g | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- 1-Benzylhexahydro-1,4-diazepine
- N-benzylhomopiperazine
- 1-Benzyl-1,4-Diazepane
- 1-Benzyl-1,4-diazacycloheptane
- 1-Benzyl-1,4-diazacycloheptanel
1-Benzyl-1,4-diazepane (BDZ) is a benzylated diazepane derivative that has been shown to have anti-cancer properties. It is used in the treatment of melanoma and other skin cancers. BDZ may be effective against cancer cells due to its localization and minimal inhibitory concentration. This drug binds to melanocortin receptors on the cell surface and enhances the release of catecholamines from nerve endings. BDZ also inhibits efflux pumps in cancer cells, which decreases their ability to pump out chemotherapeutic drugs before they can act on the cell membranes. 1-Benzyl-1,4-diazepane has been shown to be potentiated by inhibitors of esterases and microscopy assays show that it inhibits gelatinase activity. It has also been found to inhibit age-related macular degeneration in animal studies.
